Flagship startup that aims to treat ‘any disease’ raises $123M

When four-year-old biotech startup Cellarity emerged from stealth in December 2019, it laid out an ambitious vision: to combine cellular biology with machine learning to develop treatments for all diseases. Now, several high-profile investors are joining founding investor Flagship Pioneering in supporting Cellarity’s approach. The startup just closed a $123 million Series B round from funds and accounts managed by BlackRock, The Baupost Group and Banque Pictet on behalf of their clients, plus eight other investors and Flagship. With the funding, Cellarity plans to double in size this year to about 120 employees, move to a new headquarters in the second half of 2021 and further advance its drug discovery programs.